Get the Stockscreener App
0.8441
2.07%
0.0171
Mainz Biomed N V stock is traded at $0.8441, with a volume of 5.24M.
It is up +2.07% in the last 24 hours and up +12.40% over the past month.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
See More
Previous Close:
$0.827
Open:
$0.8034
24h Volume:
5.24M
Relative Volume:
10.10
Market Cap:
$10.56M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-0.0129
EPS:
-65.5728
Net Cash Flow:
$-23.84M
1W Performance:
+4.03%
1M Performance:
+12.40%
6M Performance:
-49.15%
1Y Performance:
-82.74%
1-Day Range:
$0.7391
$0.861
1-Week Range:
$0.7391
$0.8704
52-Week Range:
$0.5476
$5.34
Mainz Biomed N V Stock (MYNZ) Company Profile
Name
Mainz Biomed N V
Sector
Industry
Phone
-
Address
-
Compare MYNZ vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
0.8441 | 10.56M | 895.50K | -26.30M | -23.84M | -65.57 |
|
TMO
Thermo Fisher Scientific Inc
|
476.29 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
188.24 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
578.71 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.62 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
287.26 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Maxim Group | Buy |
| Nov-25-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-21-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-21-22 | Initiated | H.C. Wainwright | Buy |
Mainz Biomed N V Stock (MYNZ) Latest News
Mainz Biomed appoints new chairman, rebrands as Quantum Cyber - Investing.com India
Mainz Biomed Rebrands as Quantum Cyber, Appoints Robert Liscouski as Chairman, and Changes Nasdaq Ticker to QUCY - Minichart
Mainz Biomed Rebrands as Quantum Cyber, Reshapes Leadership - TipRanks
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors - GlobeNewswire
Maxim Group Downgrades Mainz Biomed (NASDAQ:MYNZ) to Hold - Defense World
David E. Lazar invests $6M in Mainz Biomed (MYNZ) preferred structure - Stock Titan
[Form 3] MAINZ BIOMED N.V. Initial Statement of Beneficial Ownership - Stock Titan
MACD Signal: What is TACTs debt to equity ratioAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples - Bitget
Mainz Biomed to Present at the Pancreatic Cancer Session at - GlobeNewswire
Is Mainz Biomed N.V. stock a top performer YTDRate Hike & Long-Term Capital Growth Ideas - mfd.ru
Press Release: Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update - 富途牛牛
Mainz Biomed (MYNZ) director granted 45,000 restricted Ordinary Shares - Stock Titan
Mainz Biomed (NASDAQ: MYNZ) grants director 45,000 Ordinary Shares - Stock Titan
Mainz Biomed secures $6 million funding, shifts focus to pancreatic cancer - Investing.com India
Mainz Biomed Announces $6 Mln Private Placement In Two Tranches To Fund Operations, Stock Down - Nasdaq
Mainz BioMed N.V. / NL0015000LC2 - AD HOC NEWS
Mainz Biomed Secures Strategic Investment and Restructures Operations - TipRanks
Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update - The Manila Times
Mainz Biomed Raises Up to $6 Million in Two-Step Preferred Stock Investment From David Lazar - TradingView
Mainz Biomed N.V. announced that it expects to receive $6 million in funding - marketscreener.com
How does Mainz Biomed N.V. compare to its peersJuly 2025 Analyst Calls & Real-Time Volume Analysis Alerts - mfd.ru
How supply chain issues affect Mainz Biomed N.V. stockJuly 2025 Macro Moves & Community Consensus Trade Alerts - mfd.ru
Mainz Biomed raises $2.15 million through at-the-market share offering - Investing.com India
Mainz Biomed completes ATM share sales, retains capacity - TipRanks
Can IDT Corporation benefit from deglobalizationWeekly Profit Summary & Community Trade Idea Sharing - baoquankhu1.vn
AI Stocks: Will AdvanSix Inc stock hit new highs in YEARCPI Data & Real-Time Sentiment Analysis - baoquankhu1.vn
What’s the beta of Mainz Biomed N.V. stockWeekly Trend Recap & AI Forecasted Entry/Exit Points - mfd.ru
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CEO and Director Guido Baechler - Longbridge
Growth Recap: How does Mainz Biomed NV compare to its peers2025 Support & Resistance & AI Powered Market Trend Analysis - baoquankhu1.vn
Aug Analyst Calls: Is Maplebear Inc stock a buy or sellJuly 2025 Big Picture & High Return Trade Guides - baoquankhu1.vn
Kevin Michael Donahue Acquires Over 643K Shares of Mainz Biomed N.V. - TradingView
Mainz Biomed N.V. to Present Innovative Cancer Detection Research at AACR 2026 Annual Meeting - Quiver Quantitative
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting - GlobeNewswire
Income Plays: How does Mainz Biomed NV compare to its peers2025 Sector Review & Risk Managed Investment Strategies - baoquankhu1.vn
CEO Moves: Will Mainz Biomed NV stock continue upward momentum - Bộ Nội Vụ
Trading Action: Why Mainz Biomed NV stock could outperform in 2025 - moha.gov.vn
Is Mainz Biomed N.V. (4TO) stock among top earnings playsWeekly Market Summary & AI Forecasted Stock Moves - Улправда
Is Mainz Biomed N.V. stock a safe buy before earningsMarket Weekly Review & Low Risk High Reward Ideas - Улправда
Earnings Report: Will Mainz Biomed N.V. stock see PE expansionJuly 2025 Big Picture & Entry Point Strategy Guides - ulpravda.ru
Entry Recap: How resilient is Mainz Biomed N.V. stock in market downturns2025 Growth vs Value & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Is Mainz Biomed N.V. (4TO) stock undervalued after correction2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
How strong is Mainz Biomed N.V. stock revenue growthMarket Sentiment Indicators & Big Gains Small Capital - ulpravda.ru
Is Mainz Biomed N.V. stock a buy for dividend growthStock Screening Results & Minimal Investment Portfolio - Улправда
Retail Trends: Will Mainz Biomed NV stock see PE expansionWeekly Profit Analysis & Safe Capital Growth Tips - moha.gov.vn
Mainz Biomed Provides Review of 2025 Highlights - Chartmill
Earnings Risk: Why analysts upgrade Pony AI Inc Depositary Receipt stock2025 Short Interest & Weekly Consistent Profit Watchlists - moha.gov.vn
Is Mainz Biomed NV a good long term investmentBullish Engulfing Patterns & Insights From Wall Street Professionals - earlytimes.in
Form 424B5 MAINZ BIOMED N.V. - StreetInsider
Mainz Biomed (NASDAQ:MYNZ) Upgraded by Wall Street Zen to Hold Rating - Defense World
Mainz Biomed (NASDAQ:MYNZ) Stock Price Up 2.7% – Still a Buy? - Defense World
Mainz Biomed N V Stock (MYNZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):